NLSPNLS PharmaceuticsNLSP info
$0.14info-3.52%24h
Global rank34575
Market cap$4.89M
Change 7d-20.81%
YTD Performance-77.17%
SP500 benchmarkUnderperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    NLS Pharmaceutics (NLSP) Stock Overview

    NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.

    NLSP Stock Information

    Symbol
    NLSP
    Address
    The Circle 6Zurich, 8058Switzerland
    Founded
    -
    Trading hours
    -
    Website
    https://nlspharma.com
    Country
    🇨🇭 Switzerland
    Phone Number
    41 44 512 21 50

    NLS Pharmaceutics (NLSP) Price Chart

    -
    Value:-

    NLS Pharmaceutics Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $0.137
    N/A
    Market Cap
    $4.89M
    N/A
    Shares Outstanding
    35.67M
    N/A
    Employees
    0
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    © 2024 Topstocks.org